Bioventus Acquires CartiHeal for $500M

Smith+Nephew Acquires CartiHeal for up to $330 Million

November 24, 2023

Medical Devices

Smith+Nephew (S&N) has agreed to acquire Israeli medtech CartiHeal for up to $330 million, adding CartiHeal's Agili‑C implant to its Sports Medicine/knee repair portfolio. CartiHeal, founded in 2009 and headquartered in Kfar Saba, Israel, employs about 25 people and has FDA breakthrough-designated technology for osteochondral repair.

Bioventus Inc. Acquires Misonix, Inc.

July 29, 2021

Medical Devices

Bioventus Inc. entered into a definitive agreement to acquire Misonix, Inc. in a cash-and-stock transaction that values Misonix at approximately $518 million on a fully diluted basis. The deal expands Bioventus' regenerative medicine and surgical solutions portfolio by adding Misonix's minimally invasive ultrasonic technologies and regenerative wound products and is expected to close in the fourth quarter of 2021 subject to customary approvals.

Bioventus Acquires Bioness, Inc.

March 30, 2021

Medical Devices

Bioventus Inc. acquired Bioness, Inc. for $45 million in up-front consideration plus up to $65 million of contingent consideration, making Bioness a wholly‑owned subsidiary. The acquisition expands Bioventus' rehabilitation and neuromodulation product portfolio and R&D pipeline, and is expected to be accretive to revenue by leveraging Bioventus' global commercial infrastructure.

Accelmed Partners Acquires Bioventus' Bioness Advanced Rehabilitation Business

October 1, 2024

Medical Devices

Bioventus has signed a definitive agreement to sell the Advanced Rehabilitation business of its subsidiary Bioness to private equity firm Accelmed Partners for total cash consideration of $45 million (including up to $20 million in earn-outs). The divestiture reduces Bioventus' annual revenue by about $50 million and allows Bioventus to focus on its core business while Accelmed plans to invest in and expand the Bioness rehabilitation product line.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.

Pacira BioSciences Acquires Flexion Therapeutics

October 11, 2021

Pharmaceuticals

Pacira BioSciences agreed to acquire Flexion Therapeutics for $8.50 per share in cash plus one contingent value right (CVR) worth up to $8.00 per share tied to sales and regulatory milestones. The deal adds Flexion's marketed non-opioid OA knee pain therapy ZILRETTA and its clinical-stage pipeline to Pacira's non-opioid pain management portfolio; the transaction was expected to close in Q4 2021 and to be accretive to Pacira's earnings.